BioSpace News Archive

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted paltusotine Orphan Drug Designation for the treatment of acromegaly.

Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced that it has commenced an underwritten public offering of its common stock.

The global blood dialyzer market has witnessed a steady growth over the years, due to the several advantages it provides to the patients with acute kidney failure.

Healthcare Providers Reported High Rates of Continued Care and Prescribing Behavior, Despite Practice-Site Restrictions Affecting >90% of the Survey Respondents

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs, announced the appointment of Stephen E. Butts to its Board of Managers.

Exact Sciences Corp. announced that the company has scheduled its virtual annual stockholders meeting and second quarter 2020 earnings call.

UROCAM Inc. is pleased to announce it has received Health Canada Approval of the COVID-19 GeneFinder™ Test Kit and is now making the test available for distribution in Canada.

AstraZeneca and Merck announced that LYNPARZA has been approved in the European Union as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.

Luminex Corporation announced 2nd quarter 2020 revenues of between $109 and $110 million, up more than 30% over the 2nd quarter of 2019.

Agreement aims to expedite local biomarker testing of NSCLC patients eligible for entrectinib in Japan